Media Thread, page-6008

‘The results showed a 41.5% reduction in the risk of death with HER-Vaxx plus SOC chemotherapy vs SOC chemotherapy alone (HR, 0.585; 80% 2-sided CI, 0.368-0.930; P = .066), favoring historical data from the phase 3 ToGA trial (NCT01041404), which resulted in a hazard ratio of 0.65 with trastuzumab (Herceptin) plus chemotherapy vs chemotherapy alone in the same patient population of patients included in the HER-Vaxx study.’

And to be eligible, you had to have had previous treatments that were ineffective AND a life expectancy of 3 months or less.

How can anyone misinterpret or not understand how good this announcement truly is.

So glad to be holding this stock. Actually, I’m exuberant.

Cheers
BD